SCHEMBL302533

SCHEMBL302533

Cc1noc(C2CCCN(C(=O)c3ccc(N(Cc4ccccc4)S(=O)(=O)c4cn(C)cn4)cc3)C2)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
HSD11B1 P28845 8/20 0.46
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.41
GRM5 P41594 1/20 0.41
CLPP Q16740 1/20 0.41
HCRTR1 O43613 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304021 0.87 PROKR1 (0.49) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL1710991 0.85 LMNA (0.47) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL302109 0.84 LMNA (0.47) ALDH1A1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL1722401 0.83 KMT2A (0.55) SMN1; SMN2KMT2ALMNAHTTMEN1
SCHEMBL1722509 0.82 PROKR1 (0.47) ALDH1A1KMT2ALMNA
SCHEMBL3275416 0.80 RAB9A (0.52) ALDH1A1SMN1; SMN2NPC1TP53MAPT
SCHEMBL303609 0.79 TP53 (0.46) ALDH1A1SMN1; SMN2NPC1TP53MAPT
SCHEMBL303569 0.79 LMNA (0.46) ALDH1A1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL303692 0.79 LMNA (0.66) ALDH1A1SMN1; SMN2NPC1KMT2ALMNA
SCHEMBL302686 0.78 LMNA (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 ALDH1A1 1588/4885TSHR 1166/4885SMN1; SMN2 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.